Recurrence rates of Barrett’s esophagus and dysplasia in patients successfully treated with radiofrequency ablation vs. cryoballoon ablation: a comparative study

Abstract

Background

Endoscopic eradication therapy (EET) is recommended for the management of dysplastic Barrett’s esophagus (BE) and intramucosal adenocarcinoma. Both radiofrequency (RFA) and cryoballoon ablation (CBA) can induce complete remission of intestinal metaplasia (CRIM). We aimed to compare long-term durability following CRIM in patients treated with RFA vs. CBA.

Methods

We conducted a retrospective cohort study to analyze patient outcomes following EET with RFA or CBA at two referral centers. We measured and compared the recurrence rate of BE, with or without dysplasia, after CRIM, using Cox proportional hazard models and propensity score-matched analyses. Our secondary aim was to identify predictors of recurrence.

Results

681 patients who achieved CRIM were included (RFA 610; CBA 71), with median follow-up of 4.1 years and 4.4 years following RFA and CBA, respectively. A multivariable model revealed a higher risk of any recurrence with RFA (hazard ratio [HR] 2.19, 95%CI 1.18–4.06; P = 0.01), but not dysplastic recurrence (HR 0.88, 95%CI 0.39–1.97; P = 0.75). However, a comparable risk of “any recurrence” was observed after excluding intestinal metaplasia of the gastroesophageal junction (HR 1.18, 95%CI 0.61–2.30; P = 0.62). Propensity score-matched analysis (54 cases in each group) showed that the two groups had comparable recurrence risk. Baseline maximum BE length was associated with a higher risk of any recurrence (HR 1.07; P<0.001) and dysplastic recurrence (HR 1.11; P = 0.001).

Conclusions

The rates of any BE recurrence and dysplastic recurrence were comparable with the two modalities in this nonrandomized study.

Publikationsverlauf

Eingereicht: 19. November 2024

Angenommen nach Revision: 30. April 2025

Accepted Manuscript online:
30. April 2025

Artikel online veröffentlicht:
28. Mai 2025

• References

• 1 Shaheen NJ, Falk GW, Iyer PG. et al. Diagnosis and management of Barrett's esophagus: an updated ACG guideline. Am J Gastroenterol 2022; 117: 559-587
• 2 Shaheen NJ, Sharma P, Overholt BF. et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. NEJM 2009; 360: 2277-2288
• 3 Phoa KN, van Vilsteren FG, Weusten BL. et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 2014; 311: 1209-1217
• 4 Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1245-1255
• 5 Pasricha S, Bulsiewicz WJ, Hathorn KE. et al. Durability and predictors of successful radiofrequency ablation for Barrett’s esophagus. Clin Gastroenterol Hepatol 2014; 12: 1840-1847
• 6 Canto MI, Trindade AJ, Abrams J. et al. Multifocal cryoballoon ablation for eradication of Barrett's esophagus-related neoplasia: A prospective multicenter clinical trial. Am J Gastroenterol 2020; 115: 1879-1890
• 7 Dbouk M, Simons M, Wang B. et al. Durability of cryoballoon ablation in neoplastic Barrett's esophagus. Techn Innov Gastrointest Endosc 2022; 24: 136-144
• 8 Agarwal S, Alshelleh M, Scott J. et al. Comparative outcomes of radiofrequency ablation and cryoballoon ablation in dysplastic Barrett’s esophagus: a propensity score− matched cohort study. Gastrointest Endosc 2022; 95: 422-431
• 9 van Munster SN, Overwater A, Haidry R. et al. Focal cryoballoon versus radiofrequency ablation of dysplastic Barrett’s esophagus: impact on treatment response and postprocedural pain. Gastrointest Endosc 2018; 88: 795-803
• 10 Sawas T, Alsawas M, Bazerbachi F. et al. Persistent intestinal metaplasia after endoscopic eradication therapy of neoplastic Barrett’s esophagus increases the risk of dysplasia recurrence: meta-analysis. Gastrointest Endosc 2019; 89: 913-925
• 11 van Vilsteren FG, Pouw RE, Seewald S. et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut 2011; 60: 765-773
• 12 Schölvinck DW, Künzli HT, Kestens C. et al. Treatment of Barrett’s esophagus with a novel focal cryoablation device: a safety and feasibility study. Endoscopy 2015; 47: 1106-1112
• 13 Krishnamoorthi R, Singh S, Ragunathan K. et al. Risk of recurrence of Barrett’s esophagus after successful endoscopic therapy. Gastrointest Endosc 2016; 83: 1090-1106
• 14 Fujii-Lau LL, Cinnor B, Shaheen N. et al. Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett’s esophagus: a systematic review and meta-analysis. Endosc Int Open 2017; 5: E430-E449
• 15 Sami SS, Ravindran A, Kahn A. et al. Timeline and location of recurrence following successful ablation in Barrett’s oesophagus: an international multicentre study. Gut 2019; 68: 1379-1385
• 16 Chandan S, Bapaye J, Khan SR. et al. Safety and efficacy of liquid nitrogen spray cryotherapy in Barrett’s neoplasia–a comprehensive review and meta-analysis. Endosc Int Open 2022; 10: E1462-E1473
• 17 Ramay FH, Cui Q, Greenwald BD. Outcomes after liquid nitrogen spray cryotherapy in Barrett's esophagus–associated high-grade dysplasia and intramucosal adenocarcinoma: 5-year follow-up. Gastrointest Endosc 2017; 86: 626-632
• 18 Overwater A, van Munster SN, Nagengast WB. et al. Novel cryoballoon 180° ablation system for treatment of Barrett’s esophagus-related neoplasia: a first-in-human study. Endoscopy 2022; 54: 64-70
• 19 Fudman DI, Lightdale CJ, Poneros JM. et al. Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus. Gastrointest Endosc 2014; 80: 71-77
• 20 Sharma P, Shaheen NJ, Katzka D. et al. AGA clinical practice update on endoscopic treatment of Barrett’s esophagus with dysplasia and/or early cancer: expert review. Gastroenterology 2020; 158: 760-769